Open AccessPrognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy
Author(s) -
Shintaro Tsukinaga,
Mikio Kajihara,
Kazuki Takakura,
Zensho Ito,
Tomoya Kanai,
Keisuke Saito,
Shiro Takami,
Hiroko Kobayashi,
Yoshihiro Matsumoto,
Shunichi Odahara,
Kan Uchiyama,
Hiroshi Arakawa,
Masato Okamoto,
Haruo Sugiyama,
Kazuki Sumiyama,
Toshifumi Ohkusa,
Shigeo Koido
Publication year - 2015
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v21.i39.11168
Subject(s) - chemoimmunotherapy , medicine , pancreatic cancer , immune system , immunology , vaccination , interleukin 2 , immunotherapy , cancer , gastroenterology , oncology
To investigate the association of plasma levels of interleukin (IL)-6 and -8 with Wilms' tumor 1 (WT1)-specific immune responses and clinical outcomes in patients with pancreatic ductal adenocarcinoma (PDA) treated with dendritic cells (DCs) pulsed with three types of major histocompatibility complex class I and II-restricted WT1 peptides combined with chemotherapy.